In non-clinical studies using cancer model mice, anti-CCR8 antibodies were shown to deplete tumor-infiltrating Tregs, increase CD8+ T cell infiltration within tumors, and enhance CD8+ T cell functions by upregulating GzmB and IFN-γ expressions 14,17. The gene discussed is CD8A; the disease is cancer.